The results confirm that LabGenius’ antibody discovery technology is able to co-optimize the pre-determined properties of a monovalent NANOBODY® protein whilst maintaining favorable production characteristics.
More generally, the partnership demonstrates that Big Pharma are committing to their pledge to put AI at the centre of their drug discovery efforts. Related Stories LabGenius is presenting the data in a poster at the Single-Domain Antibodies 2023 Meeting in Paris today. You can find the poster here.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: